Online-Trading Portfolio-Tracker Research Back-Office MF-Tracker
BSE Prices delayed by 5 minutes... << Prices as on May 08, 2024 - 9:43AM >>   ABB 6893.25 [ 0.08 ]ACC 2445.65 [ 0.35 ]AMBUJA CEM 594.9 [ 0.23 ]ASIAN PAINTS 2870.15 [ -1.42 ]AXIS BANK 1126.75 [ -0.06 ]BAJAJ AUTO 8692.75 [ 0.16 ]BANKOFBARODA 263.6 [ 1.70 ]BHARTI AIRTE 1277 [ -0.61 ]BHEL 286.4 [ 2.21 ]BPCL 615.45 [ 1.89 ]BRITANIAINDS 5192.5 [ 0.41 ]CIPLA 1384.05 [ -0.28 ]COAL INDIA 463.95 [ 1.77 ]COLGATEPALMO 2829 [ -1.15 ]DABUR INDIA 560.05 [ 0.18 ]DLF 856.95 [ 0.01 ]DRREDDYSLAB 6011.75 [ -3.95 ]GAIL 198.05 [ 2.75 ]GRASIM INDS 2415.1 [ -0.18 ]HCLTECHNOLOG 1321.1 [ -0.72 ]HDFC 2729.95 [ -0.62 ]HDFC BANK 1491.35 [ -1.00 ]HEROMOTOCORP 4426.95 [ -1.14 ]HIND.UNILEV 2350.95 [ -1.20 ]HINDALCO 622.85 [ 0.46 ]ICICI BANK 1124.6 [ -0.63 ]IDFC 115.5 [ 0.92 ]INDIANHOTELS 567.6 [ 0.26 ]INDUSINDBANK 1435 [ -1.21 ]INFOSYS 1433.45 [ -0.51 ]ITC LTD 439.65 [ -0.17 ]JINDALSTLPOW 927.3 [ 0.33 ]KOTAK BANK 1652.35 [ 0.49 ]L&T 3379.5 [ -1.55 ]LUPIN 1613.65 [ 0.19 ]MAH&MAH 2174.5 [ -0.77 ]MARUTI SUZUK 12500.95 [ 1.08 ]MTNL 35.9 [ -0.14 ]NESTLE 2507.65 [ -0.04 ]NIIT 101.9 [ -0.05 ]NMDC 266.45 [ 2.15 ]NTPC 351.5 [ 0.70 ]ONGC 275.65 [ 0.79 ]PNB 123.45 [ 0.94 ]POWER GRID 295 [ -0.08 ]RIL 2817.75 [ 0.49 ]SBI 805.15 [ 0.40 ]SESA GOA 405.45 [ 2.43 ]SHIPPINGCORP 211.75 [ 0.81 ]SUNPHRMINDS 1516.45 [ 0.09 ]TATA CHEM 1068.95 [ 0.39 ]TATA GLOBAL 1104.95 [ 0.52 ]TATA MOTORS 990.75 [ 0.26 ]TATA STEEL 165.65 [ 0.88 ]TATAPOWERCOM 436.85 [ 0.13 ]TCS 3978.25 [ 0.00 ]TECH MAHINDR 1291 [ -0.09 ]ULTRATECHCEM 9603 [ -0.88 ]UNITED SPIRI 1213.1 [ 0.89 ]WIPRO 463 [ -0.10 ]ZEETELEFILMS 134.75 [ 0.79 ] BSE NSE
You can view the entire text of Notes to accounts of the company for the latest year

BSE: 532878ISIN: INE385I01010INDUSTRY: Pharmaceuticals

BSE   ` 91.50   Open: 92.06   Today's Range 90.00
94.15
-2.40 ( -2.62 %) Prev Close: 93.90 52 Week Range 55.10
115.00
Year End :2023-03 

b) Rights, preferences and restrictions attached to shares

Equity shares: The Company has one class of equity shares having a par value of '10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

Significant Estimates : Based on the approved plans and budgets, the company has estimated that the future taxable income will be sufficient to absorb carried forward unabsorbed depreciation, which mangement believes is probable, accordingly the company has recognized deferred tax asset on aforesaid losses.

Note - "29"

Contingent Liabilities And Capital Commitment (To The Extent Not Provided For)

i) Contingent Liabilities (? in Lacs)

Particulars

As at 31st March, 2023

As at 31st March, 2022

(a) Claims against the Company not acknowledged as debts in respect of past disputed

(i) Disputed Sales Tax Dues

68.35

95.35

(ii) Disputed Income Tax Dues

27.00

27.00

(b) Guarantees

(i) Guarantees to Banks and Financial Institutions against

222.51

398.75

ii) Capital Commitment

(? in Lacs)

Particulars

As at

31st March, 2023

As at

31st March, 2022

Estimated amount of contracts remaining to be executed on capital account and not provided for (net of capital advances of ? 153.10 Lacs (31 March, 2022 : ? 153.10 Lacs))(refer note 34)

6.90

6.90

ii) Total cash outflow for leases for the year ended 31 March, 2023 was '6.26 Lakhs (P.Y. '7.02 Lakhs). (Refer note 27)

Note - "31"

Segement Reporting

As the Company operates in the single segement of drugs and chemicals which is the primary reportable segement as per Accounting Standard Ind As 108 on ‘Operating Segment ‘, no separate disclosure pertaining to the same has been given.

Note - "33"

Application for merger of Norfolk Mercantile Private Limited, Wholly owned subsidiary of Alpa laboratories Limited was filed before NCLT, Mumbai by Norfolk Mercantile Private Limited on 7th December, 2017.The same is pending before the Bench as on the date of the financial statements.

Note - "34"

(i) Court Case has been filed against Innovec Laboratories Private Limited ( Medicure Nagpur) for ' 28,94,502 (Previous Year- ' 28,94,502) for recovery of outstanding amounts.

(ii) Alpa Laboratories Limited ("The Company") has executed a registered Agreement on 24/08/2018 with Kabeer Reality Private Limited for purchase of property at Kibe Compound,Indore for a total sale consideration of '

1,60,00,000/- against which a sum of ' 1,53,10,000 was paid . On the date of registry the seller had denied to execute registry in favour of the company and to protect the rights on the property, the company had lodged a complaint in the Jurisdictional Police Station and also filed a petition in Commercial Court, Indore Division which is pending for hearing.

Note"35"

Other statutory information

a. The Company do not have any Benami property, where any proceeding has been initiated or pending against them for holding any Benami property.

b. The Company do not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income T ax Act, 1961).

c. The Company has not been declared a wilful defaulter by any bank or financial institution or other lender (as defined under the Companies Act, 2013) or consortium thereof, in accordance with the guidelines on wilful defaulters issued by the Reserve Bank of India.

d. The Company do not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

e The Company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

f The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall :

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

g The Company has not entered into any scheme of arrangement which has an accounting impact on the current or previous financial year.

h The Company has complied with the number of layers prescribed under the Companies Act, 2013.

i There were no transaction with companies struck off under section 248 of the Companies Act, 2013 or section 560 of the Companies Act, 1956 as of and for the year ended 31st March, 2023:

j The Company has not invested in any entitiy with the understanding (whether recorded in writing or otherwise) that the Company shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries).

k The Company has not advanced or loaned funds to any other person(s) or entity(ies), including foreign entities (Intermediaries).

Note - "36"

Fair Value Measurement

Financial Instrument by category and hierarchy

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following methods and assumptions were used to estimate the fair values:

1. Fair value of cash and short-term deposits, trade and other short term receivables, trade payables, other current liabilities, short term loans from banks and other financial institutions approximate their carrying amounts largely due to short term maturities of these instruments.

2. Financial instruments with fixed and variable interest rates are evaluated by the Company based on parameters such as interest rates and individual credit worthiness of the counterparty. Based on this evaluation, allowances are taken to account for expected losses of these receivables. Accordingly, fair value of such instruments is not materially different from their carrying amounts.

3. The fair values for loans and investment in preference shares were calculated based on cash flows discounted using a current lending rate. They are classified as level 3 fair values in the fair value hierarchy due to the inclusion of unobservable inputs including counter party credit risk.

4. The fair values of non-current borrowings are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk.

Fcr financial assets and liabilities that are measured at fair value, the carriying amounts are equal to the fair values.

The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

Note - "37"

Financial Risk Management

Financial risk management objectives and policies

The Company’s financial risk management is an integral part of how to plan and execute its business strategies. The Company’s financial risk management policy is set by the Managing Board.

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, equity prices and other market changes that affect market risk sensitive instruments. Market risk is attributable to all market risk sensitive financial instruments including investments and deposits, foreign currency receivables, payables and loans and borrowings.

The Company manages market risk by evaluating and exercising independent control over the entire process of market risk management. The recommend risk management objectives and policies, which are approved by Senior Management and the Audit Committee. The activities of this department include management of cash resources, implementing hedging strategies for foreign currency exposures like foreign exchange forward contracts, borrowing strategies and ensuring compliance with market risk limits and policies.

Market Risk- Foreign currency risk.

The Company operates internationally and portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk through its sales and services in overseas and purchases from overseas suppliers in various foreign currencies. Foreign currency exchange rate exposure is partly balanced by purchasing of goods, commodities and services in the respective currencies.

(a) (Hi) Market Risk- Price Risk

(a) Exposure

The Company’s exposure to equity securities price risk arises from investments held by the Company and classified in the balance sheet either at fair value through OCI or at fair value through profit and loss. To manage its price risk arising from investments in equity securities, the Company diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Company.

(b) Sensitivity

The table below summarizes the impact of increases/decreases of the BSE index on the Company’s equity and Gain/Loss for the period. The analysis is based on the assumption that the index has increased by 5 % or decreased by 5 % with all other variables held constant, and that all the Company’s equity instruments moved in line with the index.

Credit risk

Credit risk arises from the possibility that the counter party may not be able to settle their obligations as agreed. To manage this, the Company periodically assesses financial reliability of customers and other counter parties, taking into account the financial condition, current economic trends, and analysis of historical bad debts and ageing of financial assets. Individual risk limits are set and periodically reviewed on the basis of such information.

The Company considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis through each reporting period. To assess whether there is a significant increase in credit risk the Company compares the risk of default occurring on asset as at the reporting date with the risk of default as at the date of initial recognition. It considers reasonable and supportive forwarding-looking information such as:

i) Actual or expected significant adverse changes in business,

ii) Actual or expected significant changes in the operating results of the counterparty,

iii) Financial or economic conditions that are expected to cause a significant change to the counterparty’s ability to meet its obligations,

iv) Significant increase in credit risk on other financial instruments of the same counterparty,

v) Significant changes in the value of the collateral supporting the obligation or in the quality of the third-party guarantees or credit

Financial assets are written off when there is no reasonable expectations of recovery, such as a debtor failing to engage in a repayment plan with the Company. Where loans or receivables have been written off, the Company continues to engage in enforcement activity to attempt to recover the receivable due. Where recoveries are made, these are recognized as income in the statement of profit and loss.

The Company measures the expected credit loss of trade receivables and loan from individual customers based on historical trend, industry practices and the business environment in which the entity operates.Loss rates are based on actual credit loss experience and past trends. Based on the historical data, loss on collection of receivable is not materia l hence no additiona l provision considered .

Note - "38"

Capital Risk Management

a) Risk Management

The Company aim to manages its capital efficiently so as to safeguard its ability to continue as a going concern and to optimise returns to our shareholders.

The capital structure of the Company is based on management’s judgement of the appropriate balance of key elements in order to meet its strategic and day-today needs. We consider the amount of capital in proportion to risk and manage the capital structure in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders or issue new shares.

The Company’s policy is to maintain a stable and strong capital structure with a focus on total equity so as to maintain investor, creditors and market confidence and to sustain future development and growth of its business. The Company will take appropriate steps in order to maintain, or if necessary adjust, its capital structure.

Norfolk Mercantile PrivateLimited had issued 1,010 9% compulsory convertible Debentures of ' 1,00,000/- each to Alpa Laboratories Limited (holding company) in the earlier years. Due to shortage of liquidity, the Subsidiary company has went into the option of Merger with the holding Company to take the benefit of synergy. By virtue of this, the Board of Directors of the holding Company and the subsidiary company approved the Scheme of amalgamation in the nature of merger in the Board meeting held on 10th August,2017 and 11th August,2017 respectively. The Board of Director's looking into the benefit of synergy and considering the fact of pending petition of Merger before the NCLT have waived the interest amount on debentures to be paid by Norfolk Mercantile PrivateLimited to Alpa Laboratories Limited.

Note - ”42”

Dues to Micro, Small and Medium Enterprises

The Company has certain dues to suppliers registered under Micro, Small and Medium Enterprises Development Act, 2006 (‘MSMED Act’). The disclosure pursuant to the said

A/TCA/THTTA A ,-*t iifo oci 4v-,ll/n!irci*

Explanation for Variances exceeding 25%

(i) Debt Equity Ratio: Decrease in Debt Equity ratio is due to foreign currency loan repaid during the year.

(ii) Debt Services coverage Ratio: Decrease in the ratio is due to decrease in borrowings during the year.

(iii) Trade Receivable Turnover Ratio: Decrease in the ratio is due to increase in trade receivables and decrease in sales.

(iv) Return on Equity Ratio,Net Profit Ratio,Return on Capital Employed : Decrease in the ratio is due to increase in Capital Employed and decrease in EBIT during the year.

Note - ”44”

Significant Accounting Policies & Practices:

Significant accounting policies and practices adopted by the Company are disclosed in the statement annexed to these financial statements as per Annexure- "A".

Note - ”45”

Previous Years Figures:

Comparative financial information is presented in accordance with the corresponding figure reporting framework set out in standards on Auditing 710 on "Comparatives". Previous year's figures have been regrouped or arranged as wherever appropriate to correspond to figures of the current year.

Note - ”46”

The Financial Statements were authorised for issue by the directors on 29th May, 2023